Stereoselective metabolism of the monoterpene carvone by rat and human liver microsomes. 2000

W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
Institute of Pharmaceutical Chemistry, University of Vienna, Austria. wjaeger@speedy.pch.univie.ac.at

The large amounts of carvone enantiomers consumed as food additives and in dental formulations justifies the evaluation of their biotransformation pathway. The in-vitro metabolism of R-(-)- and S-(+)-carvone was studied in rat and human liver microsomes using chiral gas chromatography. Stereoselective biotransformation was observed when each enantiomer was incubated separately with liver microsomes. 4R, 6S-(-)-Carveol was NADPH-dependently formed from R-(-)-carvone, whereas 4S, 6S-(+)-carveol was produced from S-(+)-carvone. Metabolite formation followed Michaelis-Menten kinetics exhibiting a significant lower apparent Km (Michaelis-Menten Constant) for 4R, 6S-(-)-carveol compared with 4S, 6S-(+)-carveol in rat and human liver microsomes (28.4+/-10.6 microM and 69.4+/-10.3 microM vs 33.6+/-8-55 microM and 98.3+/-22.4 microM). The maximal formation rate (Vmax) determined in the same microsomal preparations yielded 30.2+/-5.0 and 32.3+/-3.9 pmol (mg protein)(-1) min(-1) in rat liver and 55.3+/-5.7 and 65.2+/-4.3 pmol (mg protein)(-1) min(-1) in human liver microsomes. Phase II conjugation of the carveol isomers by rat and human liver microsomes in the presence of UDPGA (uridine S'-diphosphogluaronic acid) only revealed glucuronidation of 4R, 6S-(-)-carveol. Vmax for glucuronide formation was more than 4-fold higher in the rat liver compared with human liver preparations (185.9+/-34.5 and 42.6+/-7.1 pmol (mg protein)(-1) min(-1), respectively). Km values, however, showed no species-related difference (13.9+/-4.1 microM and 10.2+/-2.2 microM). This study demonstrated stereoselectivity in phase-I and phase-II metabolism for R-(-)- and S-(+)-carvone and might be predictive for carvone biotransformation in man.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D003764 Dental Materials Materials used in the production of dental bases, restorations, impressions, prostheses, etc. Dental Material,Material, Dental,Materials, Dental
D005503 Food Additives Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. Additive, Food,Additives, Food,Food Additive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081005 Cyclohexane Monoterpenes Monoterpenes that include a cyclohexane ring in their structure. Monoterpenes, Cyclohexane
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
January 1991, Drug metabolism and disposition: the biological fate of chemicals,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
January 1991, Drug metabolism and disposition: the biological fate of chemicals,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
May 2012, Chirality,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
July 2006, Drug metabolism and disposition: the biological fate of chemicals,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
February 2006, European journal of clinical pharmacology,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
June 2008, Pharmaceutical research,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
March 1982, Xenobiotica; the fate of foreign compounds in biological systems,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
February 2011, Chirality,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
January 1992, Chemical research in toxicology,
W Jäger, and M Mayer, and P Platzer, and G Reznicek, and H Dietrich, and G Buchbauer
October 2002, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!